779358-35-9

Upstream product

• 779358-33-7 Acetic acid (1R,4S,5R,8R)-4-benzenesulfinylmethyl-8-methyl-4-phenyl-2,3-dioxa-bicyclo[3.3.1]non-8-yl ester 
• 779358-32-6 Acetic acid (1R,4S,5R,8R)-8-methyl-4-phenyl-4-phenylsulfanylmethyl-2,3-dioxa-bicyclo[3.3.1]non-8-yl ester 
• 779358-28-0 (1R,4S,5R,8R)-8-Methyl-4-phenyl-4-phenylsulfanylmethyl-2,3-dioxa-bicyclo[3.3.1]nonan-8-ol 
• 779358-27-9 (1R,5R,8R)-8-Methyl-4-phenyl-4-phenylsulfanylmethyl-2,3-dioxa-bicyclo[3.3.1]non-8-yl-hydroperoxide 
• 779358-25-7 Trifluoro-methanesulfonic acid 1-((R)-4-methyl-cyclohex-3-enyl)-vinyl ester 
• 779358-26-8 [1-((R)-4-Methyl-cyclohex-3-enyl)-vinyl]-benzene 
• 4680-24-4 cis-(R)-limonene oxide 
• 6090-09-1 methyl-[(1R)-4-methylcyclohex-3-enyl]ketone 
• 1449-46-3 benzyltriphenylphosphonium bromide 
• 779358-34-8 Acetic acid (1R,4S,5R,8R)-4-formyl-8-methyl-4-phenyl-2,3-dioxa-bicyclo[3.3.1]non-8-yl ester 

Downstream Products

• 614-47-1 1,3-diphenyl-propen-3-one 

Relevant academic research and scientific papers

Design and synthesis of endoperoxide antimalarial prodrug models

A masked combination chemotherapy which relies on the embedding of a number of active components, in a latent form, within a single endoperoxidic chemical entity is the aim of the research presented. The approach is illustrated by means of purposely designed bicyclic endoperoxide prodrug prototypes 1 and subsequently validated through the study of model compounds 2 (Ar= Ph, p-FC 6H4, p-ClC6H4.